PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Guselkumab - Psoriatic arthritis

PAD Profile : Guselkumab - Psoriatic arthritis

Keywords :
PsA, biologic NICE, cytokine modulator, immunosuppressant, DMARD, Bdmard, Disease modulating, Rheumatology, Interleukin, IL23, monoclonal antibody, interleukin (IL)-23 protein, DNA technology
Brand Names Include :
Tremfya

Traffic Light Status

Status 1 of 1.

Status :
Red
Formulations :
  • Subcutaneous injection (sc)
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
03 April 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed the reviewed and updated Psoriatic Arthritis pathway.

05 October 2022
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands integrated care system Area Prescribing Committee (APC) approve guselkumab as an option for treating active psoriatic arthritis in adults whose disease has not responded well enough to disease-modifying antirheumatic drugs (DMARDs) or who cannot tolerate them, in line with NICE TA815.  Please see the current treatment pathway below.

Guselkumab for this indication will be considered as RED on the traffic light status (treatment should be initiated and continued by specialist clinicians).

Primary care prescribers should be aware that their patient is receiving this medicine and ensure that this is recorded on the patient’s medication screen as a hospital-only drug in line with guidance on the PAD. This will also alert the prescriber to potential side effects and interactions with other medicines prescribed in primary care. It will also ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.

Associated BNF Codes

10. Musculoskeletal and Joint Diseases
10.01.03. Rheumatic disease suppressant drugs
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More